COMPASS Pathways Projects 2027 Commercialization Timeline For Psilocybin Therapy
Portfolio Pulse from The Dales Report
COMPASS Pathways (NASDAQ:CMPS) has projected a 2027 commercialization timeline for its psilocybin-assisted therapy, pending Phase 3 clinical trial success. The company is currently conducting a Phase 3 clinical program for its proprietary psilocybin formula, COMP360, for treatment-resistant depression. Additionally, COMPASS is undertaking concurrent Phase 2 clinical studies using COMP360 for PTSD and anorexia nervosa. H.C. Wainwright reiterated their 'Buy' rating on COMPASS Pathways, maintaining its $120 per share price target.
July 07, 2023 | 3:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
COMPASS Pathways' projected 2027 commercialization timeline for its psilocybin therapy and the 'Buy' rating from H.C. Wainwright could positively impact the company's stock in the short term.
The projected commercialization timeline indicates progress in COMPASS Pathways' clinical trials, which could boost investor confidence. Additionally, the 'Buy' rating from H.C. Wainwright signals positive market sentiment towards the company.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100